Teva Pharmaceutical Industries Ltd. announced a proposal to acquire all of the outstanding shares of Mylan N.V. in a transaction...
Mylan N.V. announced that it has officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo Company...
Teva Pharmaceutical Industries announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary...
Mylan N.V. announced that the FDA has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL...
Mylan N.V. and Biocon Ltd. announced that the FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed...
Mylan N.V. announced that Mylan has made a proposal to acquire Perrigo Company plc in a cash-and-stock transaction that would...
The Board of Directors of Meda AB hereby confirms that it has been contacted by Mylan, Inc.regarding an indicative proposal...
Mylan N.V. announced that the U.S. District Court for the Northern District of West Virginia invalidated Biogen's Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description.
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation...
Mylan Inc. announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40...